125 related articles for article (PubMed ID: 3912620)
21. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Hartman AR; Fleming GF; Dillon JJ
Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
[TBL] [Abstract][Full Text] [Related]
24. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Zambetti M; Veronesi U
Breast Cancer Res Treat; 1985; 5(2):95-115. PubMed ID: 3839424
[TBL] [Abstract][Full Text] [Related]
25. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemo-immunotherapy in stage II carcinoma of the breast.
Giuliano AE; Sparks FC; Patterson K; Spears I; Morton DL
J Surg Oncol; 1986 Apr; 31(4):255-9. PubMed ID: 3523043
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
28. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
30. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Lippman ME; Cassidy J; Wesley M; Young RC
J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Eur J Cancer (1965); 1980; Suppl 1():189-95. PubMed ID: 7032932
[No Abstract] [Full Text] [Related]
34. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
Oriana S; Coradini D; Sasso GM; Di Fronzo G
Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
37. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
39. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
40. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]